Drug research

BXCL501

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Dexmedetomidine

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510	BioXcel Therapeutics Inc	Phase 3	Completed	2025-08-15Actual
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaNCT05276830	BioXcel Therapeutics Inc	Phase 2	Terminated	2022-04-01Actual
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)NCT05665088	BioXcel Therapeutics Inc	Phase 3	Terminated	2023-09-11Actual
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)NCT05271552	BioXcel Therapeutics Inc	Phase 3	Completed	2023-04-21Actual

BioXcel Therapeutics IncCompletedPrimary completion: 2025-08-15 · Actual

Trial details

BioXcel Therapeutics IncTerminatedPrimary completion: 2022-04-01 · Actual

Trial details

BioXcel Therapeutics IncTerminatedPrimary completion: 2023-09-11 · Actual

Trial details

BioXcel Therapeutics IncCompletedPrimary completion: 2023-04-21 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.